The Emerging Role of Degenerative Cervical Myelopathy Immunology

Degenerative cervical myelopathy (DCM) stands as the leading cause of non-traumatic spinal cord impairment in adults. While clinicians traditionally view DCM through the lens of mechanical compression, recent evidence highlights the critical importance of Degenerative Cervical Myelopathy immunology. Chronic spinal cord compression triggers a complex cascade of neuroinflammation, ischemia, and subsequent axonal damage. Furthermore, researchers now recognize that the immune system actively drives the neurological progression of the disease rather than merely reacting to mechanical injury.

A systematic review of current literature identifies several key immunological markers in the cerebrospinal fluid (CSF) and peripheral blood of affected patients. Specifically, elevated proinflammatory cytokines, such as interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α), indicate a sustained inflammatory environment. Moreover, histological studies reveal increased staining for activated myeloid cells and Fas-mediated apoptosis within the spinal cord tissue. These findings suggest that immune-mediated cell death significantly contributes to the chronic neurodegeneration seen in DCM.

Biomarkers and Clinical Outcomes

Identifying reliable biomarkers remains essential for improving surgical decision-making and predicting patient recovery. Notably, perioperative levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in the CSF correlate with favorable clinical outcomes following decompression. Additionally, serum S100b values serve as a potential postoperative indicator of neurological improvement. Consequently, integrating these markers into routine clinical practice could help surgeons better identify patients who are likely to benefit most from intervention.

Furthermore, peripheral immune profiling has revealed shifts in macrophage and T-cell populations. Patients with DCM often exhibit increased levels of M2 macrophages and activated CD4 T cells. These cellular changes reflect a systemic response to the localized spinal cord injury. Understanding Degenerative Cervical Myelopathy immunology may eventually lead to targeted immunotherapies that complement traditional surgical decompression, potentially halting disease progression in its early stages.

FAQ: Degenerative Cervical Myelopathy Immunology

Which immune markers are most significant in DCM?

Key markers include proinflammatory cytokines like IL-8 and TNF-α, along with structural proteins such as neurofilament light chain (NfL) and GFAP, which indicate axonal and glial injury.

Can immune profiling predict surgical success?

Yes, research shows that certain perioperative CSF and serum biomarkers, including S100b and NfL, correlate significantly with clinical improvement and functional outcomes after surgery.

How does inflammation cause damage in the spinal cord?

Inflammation in DCM leads to blood-spinal cord barrier disruption, apoptosis via Fas-mediated pathways, and impaired autophagy, all of which exacerbate neurodegeneration.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.

References

Chabot PJ et al. Characterizing immune involvement in degenerative cervical myelopathy: a systematic review. J Neurosurg Spine. 2026 May 01. doi: 10.3171/2025.12.SPINE251122. PMID: 42066366.

Vedantam A et al. Serum protein biomarkers for degenerative cervical myelopathy: a prospective study. J Neurosurg Spine. 2025 Apr 11;42(6):718-726. doi: 10.3171/2025.1.SPINE241085.

Nouri A et al. Degenerative Cervical Myelopathy: Epidemiology, Genetics, and Pathogenesis. Spine (Phila Pa 1976). 2015 Oct 15;40(20):E1075-93. doi: 10.1097/BRS.0000000000001013.